This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
by Zacks Equity Research
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
5 Sectors and Stocks Set to Shine This Earnings Season
by Sweta Killa
We have highlighted stocks from the sectors that are expected to move higher this earnings season.
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues
by Zacks Equity Research
QDEL's preliminary fourth-quarter revenues align with the company's expectations.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
by Zacks Equity Research
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
Scoop Up These 4 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. OUT, COR, RJF and RMD are some stocks that hold promise.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
by Zacks Equity Research
Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
by Zacks Equity Research
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
Zacks.com featured highlights Chipotle Mexican Grill, ResMed and ServiceNow
by Zacks Equity Research
Chipotle Mexican Grill, ResMed and ServiceNow have been highlighted in this Screen of The Week article.
GMED Stock Rides on NuVasive Synergy Benefits Amid Macro Issues
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Neogen (NEOG) Q2 Earnings Match Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
MYGN Stock Gains Following Collaboration With Hannah Storm
by Zacks Equity Research
Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program ambassador.
3 S&P 500 Earnings Growth Stocks to Buy in 2025: CMG, RMD, NOW
by Tirthankar Chakraborty
Chipotle Mexican Grill, Ulta Beauty and ServiceNow are currently exhibiting superb earnings growth.
Expanding Global Network, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies.
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
by Zacks Equity Research
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Add Accuray Stock to Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
by Zacks Equity Research
OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.
QGEN Stock Might Rise Following Partnership With Genomics England
by Zacks Equity Research
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?
by Zacks Equity Research
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.